The results of a recent study that was published in the journal of Circulation, suggest that low-density lipoprotein ...

Elevated Remnant Cholesterol tied to increased ASCVD events in Individuals With Diabetes suggests a study published in the ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage ...

Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans fats to promote atherosclerotic cardiovascular disease (ASCVD), explaining ...

A study was conducted to determine the association between housing unaffordability and health outcomes and medication ...

Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans fat-induced atherosclerosis - (https:/ ...

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

On Monday, Silence Therapeutics plc (NASDAQ:SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of ...

Silence Therapeutics (SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA, or siRNA, ...

The recently launched National Action Plan on Obesity, Diabetes, and Modifiable Risk Factors for Atherosclerotic ...

THE Philippine Press Institute (PPI) has spearheaded a health reporting workshop to help local journalists gain a deeper ...